Previous 10 | Next 10 |
EDWARDS LIFESCIENCES REPORTS THIRD QUARTER RESULTS PR Newswire IRVINE, Calif. , Oct. 27, 2022 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended September 30, 2022. Third Quarter...
Edwards Lifesciences ( NYSE: EW ) is scheduled to announce Q3 earnings results on Thursday, October 27th, after market close. The consensus EPS Estimate is $0.62 and the consensus Revenue Estimate is $1.33B (+1.5% Y/Y). Over the last 2 years, EW has beaten EPS estima...
EDWARDS LIFESCIENCES TO HOST EARNINGS CONFERENCE CALL ON OCTOBER 27, 2022 PR Newswire IRVINE, Calif. , Oct. 20, 2022 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended September 30, 2022 ...
Summary We discuss our top performance detractors and contributors for the third quarter. We present an in-depth company commentary about Alphabet. We lead off this letter with the same Ford Administration WIN graphic from our last letter and a short summary. Fed to ...
Palm Beach, FL – October 4, 2022 – FinancialNewsMedia.com News Commentary – The laser therapy market has been having a very health growth trend in recent years and is expected to continue through the coming years. Minimally invasive surgical procedures...
Summary Wedgewood Partners’ 13F portfolio value decreased from $709M to $579M this quarter. They added Pool Corp and increased PayPal Holdings and First Republic Bank while reducing Visa, Tractor Supply, Progressive Corporation, and Starbucks. Their top five positions a...
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...
Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week. The newsletter keeps you informed of the biggest stories set to make headlines, including upcoming IPOs, investor days, earnings reports and conference presentat...
EDWARDS ANNOUNCES SIX-MONTH DATA CONFIRMING TEER AS SAFE AND EFFECTIVE FOR DMR IN FIRST HEAD-TO-HEAD TRIAL PR Newswire BOSTON , Sept. 17, 2022 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) announced results from CLASP IID, the first randomiz...
The US FDA has approved Edwards Lifesciences' ( NYSE: EW ) PASCAL Precision transcatheter valve repair system for transcatheter edge-to-edge repair. The system is used for patients with degenerative mitral regurgitation. It is also engineered with an intuitive cat...
News, Short Squeeze, Breakout and More Instantly...
Edwards Lifesciences Corporation Company Name:
EW Stock Symbol:
NYSE Market:
Edwards Lifesciences Corporation Website:
Edwards Lifesciences (NYSE: EW) today announced investments that reflect the company’s deep commitment to advancing patient care through structural heart innovation, addressing large unmet patient needs and supporting sustainable long-term growth. Edwards has entered into an agreement ...
Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended June 30, 2024 after the market closes on Wednesday, July 24, 2024, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877)...
Edwards Lifesciences (NYSE: EW) today announced it has exercised its option to acquire Innovalve Bio Medical Ltd., an early-stage transcatheter mitral valve replacement (TMVR) company, following its initial investment in 2017. Since that time, Innovalve has demonstrated progress in its program wi...